Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ascites Clear all
Completed Early Phase 1 Interventional

Autologous OC-DC Vaccine in Ovarian Cancer

NCT01132014
View directory record Official record
Conditions
Chemotherapy, Tumor, Ovarian Cancer
Interventions
OCDC
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Jul 21, 2026, 11:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective Natural History Study of Lymphatic Anomalies

NCT05731141
View directory record Official record
Conditions
Lymphatic Diseases, Lymphatic Abnormalities
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 100 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Withdrawn Phase 2 Interventional

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

NCT00005645
View directory record Official record
Conditions
Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
ILX-295501
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Jul 21, 2026, 11:56 AM EDT
Recruiting Not applicable Interventional

Transitional Care Program for Fluid Overload in Cirrhosis

NCT06174272
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
Transitional Care Program
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Terminated Not applicable Interventional Results available

Achieving Portal Access With Scorpion Post-Approval Study (APASS)

NCT05765253
View directory record Official record
Conditions
Portal Hypertension, Liver Diseases, Ascites Hepatic, Hydrothorax, Vascular Diseases
Interventions
Scorpion Portal Vein Access Kit, Cook Transjugular Liver Access Set, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Device · Procedure
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Atlanta, Georgia • New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jul 21, 2026, 11:56 AM EDT
Terminated Phase 2 Interventional

Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites

NCT00265863
View directory record Official record
Conditions
Metastatic Cancer
Interventions
mitomycin C
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jul 21, 2026, 11:56 AM EDT
Recruiting No phase listed Observational

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies

NCT03943316
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Not listed
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Timeline
2015 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

NCT00182754
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
octreotide acetate, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
122
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Jul 21, 2026, 11:56 AM EDT
Terminated Not applicable Interventional Results available

Early TIPS for Ascites Study

NCT01236339
View directory record Official record
Conditions
Liver Cirrhosis, Portal Hypertension, Ascites
Interventions
TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis, LVP, TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol
Device · Procedure
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 69 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Tucson, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 3 Interventional Results available

A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

NCT01143246
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Terlipressin, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 3 Interventional

Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)

NCT00358878
View directory record Official record
Conditions
Ascites, Liver Cirrhosis
Interventions
Satavaptan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 4 Interventional Results available

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

NCT00108355
View directory record Official record
Conditions
Ascites, Cirrhosis
Interventions
Albumin, Intravenous Saline Infusion (Albumin placebo), Midodrine, Oral tablet (Midodrine placebo), Octreotide LAR, Saline injection (Octreotide LAR placebo), Large Volume Paracentesis
Drug · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites

NCT02608658
View directory record Official record
Conditions
Cirrhosis of the Liver, Ascites, Spontaneous Bacterial Peritonitis
Interventions
Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

NCT04384523
View directory record Official record
Conditions
Ascites Hepatic
Interventions
OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV, OsrHSA 140 mg/kg IV, OsrHSA 200 mg/kg IV, Placebo
Drug · Other
Lead sponsor
Healthgen Biotechnology Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Jul 21, 2026, 11:56 AM EDT
Completed No phase listed Observational

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430
View directory record Official record
Conditions
Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

NCT00005906
View directory record Official record
Conditions
Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
Interventions
Octreotide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Jul 21, 2026, 11:56 AM EDT
Recruiting Phase 2 Interventional

High Dose Albumin in Refractory Ascites

NCT05867602
View directory record Official record
Conditions
Ascites
Interventions
Albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Not applicable Interventional

Non-Pharmaceutical Intervention for Cirrhotic Cramps Reduction: The NICCles Trial

NCT04650295
View directory record Official record
Conditions
Cirrhosis, Muscle Cramp, Ascites
Interventions
Household Remedy, Tap water
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Jul 21, 2026, 11:56 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)

NCT03682744
View directory record Official record
Conditions
Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer, Breast Cancer, Pancreas Cancer, Carcinoembryonic Antigen
Interventions
anti-CEA CAR-T cells
Biological
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
New Brunswick, New Jersey • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 21, 2026, 11:56 AM EDT
Withdrawn Phase 2 Interventional

A Study of Bevacizumab to Prevent Malignant Ascites

NCT00908219
View directory record Official record
Conditions
Malignant Ascites
Interventions
Bevacizumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 21, 2026, 11:56 AM EDT
Terminated Not applicable Interventional

Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome

NCT00734136
View directory record Official record
Conditions
Hepatorenal Syndrome, Renal Failure, Liver Diseases
Interventions
Blood Draws and a hepatectomy specimen, Blood draw - pre operative standard of care
Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2009 · Synced Jul 21, 2026, 11:56 AM EDT
Terminated Phase 4 Interventional

Sodium Restriction in the Management of Cirrhotic Ascites

NCT00548366
View directory record Official record
Conditions
Ascites
Interventions
Sodium restriction
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Jul 21, 2026, 11:56 AM EDT
Completed Phase 3 Interventional

North American Study for the Treatment of Refractory Ascites (NASTRA)

NCT00006166
View directory record Official record
Conditions
Ascites, Liver Cirrhosis
Interventions
Transjugular intrahepatic portasystemic shunts (TIPS), Total paracentecis (TP)
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
5
States / cities
Miami, Florida • Omaha, Nebraska • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 21, 2026, 11:56 AM EDT
Not listed Not applicable Interventional

Utility of 2- Octyl Cyanoacrylate (2-OCA)

NCT05278013
View directory record Official record
Conditions
Ascites, Fluid Loss
Interventions
Dermabond
Other
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Jul 21, 2026, 11:56 AM EDT